Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533990 | 0.85 | ALDH1A1 (0.60) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL10403688 | 0.85 | ALDH1A1 (0.60) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL11518064 | 0.84 | ALDH1A1 (0.58) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL11166347 | 0.84 | ALDH1A1 (0.58) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL9547388 | 0.84 | ALDH1A1 (0.58) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL10786625 | 0.82 | ALDH1A1 (0.56) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL10457059 | 0.82 | ALDH1A1 (0.56) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL9805552 | 0.81 | ALDH1A1 (0.55) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL6086755 | 0.81 | ALDH1A1 (0.58) | ALDH1A1POLBGAAALOX15HSD17B10 | |
| SCHEMBL14605923 | 0.81 | ALDH1A1 (0.55) | ALDH1A1POLBGAAALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662205-B2 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190084999-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2017-10-26 | — | — | US | disclosed |
| US-9642869-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642869-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642869-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| WO-2016081297-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| EP-2941246-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9101638-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101638-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20120122889-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-17 | — | — | US | disclosed |
| US-5811419-A | ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5494666-A | BETA-LACTAMASE INHIBITORS, ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| US-4766120-A | ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1988-08-23 | — | — | US | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
| US-4663323-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0035046-B1 | NOVEL TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4540703-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-09-10 | — | — | US | disclosed |
| EP-0035046-A1 | Novel tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122889-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | ALDH1A1 4844/4885POLB 2233/4885GAA 1664/4885 |
| US-20170305824-A1 | SMALL MOLECULE INHIBITORS OF NECROPTOSIS | TNF, TNFRSF1A, RIPK1 | ALDH1A1 4840/4885POLB 2287/4885GAA 1670/4885 |
| US-20190084999-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BCL9 | ALDH1A1 2726/4885POLB 1093/4885GAA 152/4885 |
| US-10662205-B2 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | BCL6B, BCL6, BCL9 | ALDH1A1 2726/4885POLB 1093/4885GAA 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.